We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Provention Bio has filed to raise up to $50 million in its Nasdaq IPO, which will bankroll several clinical programs, including a pair of inflammatory bowel disease assets it picked up from Janssen last fall.